RBC Capital Maintains Outperform on Insmed, Lowers Price Target to $205

Benzinga Newsdesk www.benzinga.com Negative 94.7%

Neg 94.7% Neu 0% Pos 0%

RBC Capital analyst Leonid Timashev maintains Insmed (NASDAQ:INSM) with a Outperform and lowers the price target from $220 to $205.